Kaos Capital Pushes for Strategic Change at Capricor Therapeutics Amid Financial Concerns

Overview of Kaos Capital's Call to Action

On August 21, 2026, Kaos Capital Ltd., a significant shareholder of Capricor Therapeutics, Inc. (NASDAQ: CAPR), expressed its concerns regarding the company’s financial stability and governance. In a letter addressed to fellow shareholders, Kaos Capital outlined a series of necessary actions aimed at safeguarding the company's assets and ensuring a sustainable future. The demands include an immediate meeting with Capricor's Board of Directors, the nomination of independent directors, and the establishment of a strategic committee. This proactive approach underscores the urgency felt by shareholders as Capricor experiences financial strains.

Current Financial Landscape

Capricor's recent financial report indicated alarming figures, with cash reserves falling to $237.9 million as of June 30, 2026—down nearly $80.2 million from the previous year's end. The company incurred operating expenses totaling $79.7 million in the first half of 2026, including a hefty general and administrative expense of $23.5 million, nearly double that of the previous year. This troubling financial outlook necessitates immediate action to preserve cash and ensure the company’s long-term viability.

Immediate Meeting Request

Kaos Capital is demanding an urgent meeting with Capricor’s Board of Directors. They expect the Board to confirm this meeting in writing within five business days, aiming for it to occur no later than fifteen business days from the letter’s date. The agenda for this meeting should focus on strategies to preserve the company’s cash reserves, refresh the Board composition, and consider acquisition opportunities that align with the company's core capabilities in cell therapy and exosome technologies.

Governance Reform: A Shareholder-Led Initiative

One key proposal from Kaos Capital is the nomination of two independent directors who possess significant experience in biotechnology transactions and corporate governance. The aim is to form a newly established M&A and Strategic Alternatives Committee led by a shareholder-backed director. This independent committee would ensure that the perspectives of long-term shareholders are taken into account in strategic discussions and decisions regarding the company’s future.

Focus on Cash Preservation

In light of the company’s increasing operating costs, Kaos Capital emphasizes the necessity of adopting a Cash Preservation Plan. They advocate for a detailed review of all discretionary expenses, aiming to identify non-essential areas of spending. Additionally, a zero-based review of general and administrative costs should be implemented, alongside clear guidelines for material financial commitments. The goal is to facilitate conscious financial management that prioritizes cash conservation without compromising essential operations.

A Broader Biotech Strategy

Rather than merely concentrating on the current lead program, deramiocel, Kaos Capital stresses the importance of diversifying Capricor’s business model. They encourage the Board to explore opportunities for acquisitions, licenses, or partnerships that can effectively leverage the existing strengths in cell-therapy and exosome capabilities. This strategic expansion could mitigate existing risks by fostering a more multifaceted biotechnology enterprise, thus opening new value-generating avenues in the marketplace.

Addressing Legal Challenges

In addition to financial and governance restructuring, Kaos Capital is calling for the Board to engage top-tier legal advisors to navigate the numerous legal challenges facing Capricor, including ongoing shareholder litigations and other disputes. By resolving these issues proactively, Capricor can shift its focus back to growth and innovation, transforming its corporate culture into one that prioritizes shareholder engagement and accountability.

Conclusion

Kaos Capital’s assertive stance reflects the growing discontent among shareholders regarding the management of Capricor Therapeutics. The outlined strategies indicate a clear path forward that not only seeks immediate action but also aims to build a robust framework for sustained growth and governance reform. As investors await the Board's response, the future of Capricor hinges on their ability to adapt and implement these necessary changes for the common good of its stakeholders.